Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 50


The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis.

Herrington CS, McCluggage WG.

J Pathol. 2010 Jan;220(1):5-6. doi: 10.1002/path.2630.


Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.

Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, Blandino G, Costanzo A, Sakaguchi K, Tuosto L.

Cell Cycle. 2009 Oct 15;8(20):3396-405. Epub 2009 Oct 24.


Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Vang R, Shih IeM, Kurman RJ.

Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Review.


When mutants gain new powers: news from the mutant p53 field.

Brosh R, Rotter V.

Nat Rev Cancer. 2009 Oct;9(10):701-13. doi: 10.1038/nrc2693. Epub 2009 Aug 20. Review.


Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH.

Br J Cancer. 2009 Jul 7;101(1):149-59. doi: 10.1038/sj.bjc.6605112. Epub 2009 Jun 9.


Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.

Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM.

Am J Pathol. 2009 May;174(5):1597-601. doi: 10.2353/ajpath.2009.081000. Epub 2009 Apr 6.


High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.


Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D; AOCS Study Group.

Clin Cancer Res. 2009 Feb 15;15(4):1417-27. doi: 10.1158/1078-0432.CCR-08-1564. Epub 2009 Feb 3.


Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D.

PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232.


Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Dec;111(3):487-95. doi: 10.1016/j.ygyno.2008.08.020. Epub 2008 Oct 2.


Recent advances in p53 research: an interdisciplinary perspective.

Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P.

Cancer Gene Ther. 2009 Jan;16(1):1-12. doi: 10.1038/cgt.2008.69. Epub 2008 Sep 19. Review.


An integrated genomic analysis of human glioblastoma multiforme.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.


The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G.

Genes Dev. 2008 May 15;22(10):1337-44. doi: 10.1101/gad.1662908.


Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.

Høgdall EV, Christensen L, Høgdall CK, Frederiksen K, Gayther S, Blaakaer J, Jacobs IJ, Kjaer SK.

APMIS. 2008 May;116(5):400-9. doi: 10.1111/j.1600-0463.2008.00917.x.


PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, Johnson E, Lal B, Hussaini I, Bao Y, Laterra J, Schiff D, Abounader R.

Cancer Res. 2008 Mar 15;68(6):1723-31. doi: 10.1158/0008-5472.CAN-07-1963.


TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.

Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M; Polish Ovarian Cancer Study Group (POCSG).

BMC Cancer. 2008 Jan 29;8:27. doi: 10.1186/1471-2407-8-27.


Estimation and assessment of raw copy numbers at the single locus level.

Bengtsson H, Irizarry R, Carvalho B, Speed TP.

Bioinformatics. 2008 Mar 15;24(6):759-67. doi: 10.1093/bioinformatics/btn016. Epub 2008 Jan 19.


Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.

Bartel F, Jung J, Böhnke A, Gradhand E, Zeng K, Thomssen C, Hauptmann S.

Clin Cancer Res. 2008 Jan 1;14(1):89-96. doi: 10.1158/1078-0432.CCR-07-1192.


Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.

Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM, Webb PM; Australian Cancer Study Group (ovarian cancer); Australian Ovarian Cancer Study Group.

Int J Cancer. 2008 Apr 1;122(7):1598-603.


Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.

Salani R, Kurman RJ, Giuntoli R 2nd, Gardner G, Bristow R, Wang TL, Shih IM.

Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91. Epub 2007 Aug 10.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk